Mae Vertex Pharmaceuticals yn gwneud sawl meddyginiaeth i drin ffeibrosis systig, gan gynnwys Orkambi® (lumacaftor/ivacaftor).  Penderfynodd y dylai Orkambi®, ar gyfer cleifion sy’n 12 oed neu’n hŷn, gael ei gwerthuso gan NICE.  Ym mis Gorffennaf 2016 nid argymhellodd NICE hi. Daeth NICE i’r casgliad nad oedd Orkambi® yn gost-effeithiol.  Gwerthusodd yr SMC yn yr Alban Orkambi® yn 2016 hefyd ond nid argymhellodd hi.  Yn 2017, ailgyhoeddodd NICE ei argymhelliad yn ganllawiau “Do Not Do” gan bwysleisio na ddylai’r driniaeth hon fod ar gael fel rheol.
Vertex Pharmaceuticals manufacture several medicines to treat cystic fibrosis, including Orkambi® (lumacaftor/ivacaftor). They chose to have Orkambi®, for patients aged 12 and over, appraised by NICE. In July 2016, NICE did not recommend it. NICE concluded the Orkambi® was not cost-effective. The SMC in Scotland also appraised Orkambi® in 2016 but did not recommend it. In 2017, NICE re-issued its recommendation as “Do Not Do” guidance, emphasising this treatment should not be routinely available.